DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Could HER2 Heterogeneity Open New Therapeutic Options in Patients with HER2-Primary Breast Cancer
Technical Report,30 Sep 2015,29 Sep 2016
Memorial Sloan Kettering Cancer Center New York United States
Pagination or Media Count:
The purpose of this study is to determine if targeted imaging with a HER2-targeting PET tracer can detect HER2-positive metastases inpatients with HER2-negative primary breast cancer. Twenty-three patients have been accrued to the trial. Nine patients demonstrated suspicious foci on 89Zr-trastuzumab PETCT. Two of nine patients with suspicious foci had biopsy-proven HER2-positive metastases. Thus, 89Zr-trastuzumab PETCT may detect HER2-positive metastases in patients with presumed HER2-negtive primary breast cancer. This is an initial proof-of-concept that targeted imaging may help identify patients eligible for targeted therapies. However, false-positive results limit the ability of 89Zr-trastuzumab to be translated into clinical use, and a more specific radiotracer will be needed.
APPROVED FOR PUBLIC RELEASE